MOTS-c vs SS-31

Overview

MOTS-c and SS-31 (elamipretide) both target mitochondrial function but represent fundamentally different approaches. MOTS-c is an endogenous mitochondria-derived peptide that acts as a metabolic regulator and exercise mimetic through AMPK activation. SS-31 is a rationally designed synthetic peptide that directly binds cardiolipin on the inner mitochondrial membrane. One is endogenous signaling, the other is direct structural intervention.

This comparison contrasts endogenous peptide biology with synthetic drug development in the mitochondrial aging field.

Key Facts

Aspect	MOTS-c	SS-31 (Elamipretide)
Type	Endogenous MDP	Synthetic peptide drug
Structure	16 amino acids	Tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2)
Origin	Mitochondrial DNA (12S rRNA)	Rational design
Discovery	2015 (Cohen lab)	2000s (Szeto)
Clinical Status	No trials	Phase 2/3 trials
FDA Status	Not approved	Investigational

Development Status

Aspect	MOTS-c	SS-31
Research Phase	Academic/preclinical	Clinical trials
Commercial Development	None	Active (Stealth Bio)
Patent Status	Research	Protected
Path to Market	None	Active

Mechanism Comparison

Aspect	MOTS-c	SS-31
Primary Target	AMPK pathway	Cardiolipin
Action Site	Cytoplasm/nucleus	Inner mitochondrial membrane
Mechanism	Signaling cascade	Direct membrane binding
Effect	Metabolic reprogramming	ETC optimization

MOTS-c Mechanisms

1. AMPK Activation

   • Master metabolic regulator
   • Shifts cells to maintenance mode
   • Mimics exercise effects
   • mTOR suppression

2. Nuclear Translocation

   • Enters nucleus under stress
   • Nrf2-ARE pathway activation
   • Antioxidant gene expression
   • Direct gene regulation

3. Metabolic Effects

   • Improved glucose uptake
   • Enhanced insulin sensitivity
   • Fatty acid oxidation
   • Exercise mimetic properties

SS-31 Mechanisms

1. Cardiolipin Binding

   • Binds inner membrane phospholipid
   • Optimizes cytochrome c interactions
   • Stabilizes respiratory complexes
   • Membrane structural support

2. Mitochondrial Concentration

   • 1000-5000x accumulation
   • Rapid uptake
   • Targets ROS source
   • Independent of membrane potential

3. Bioenergetic Improvement

   • Increased ATP efficiency
   • Reduced electron leak
   • Protected cristae structure
   • Improved respiration

Evidence Quality

Factor	MOTS-c	SS-31
Human RCTs	None	Multiple Phase 2/3
Human Safety Data	None	Established
Human Biomarker Data	Yes	N/A
Preclinical Data	Growing	Extensive
Overall Evidence	Low	Moderate

MOTS-c Evidence

Type	Status	Key Findings
Animal studies	Growing	Metabolic improvements, healthspan
Cell studies	Extensive	AMPK mechanism confirmed
Human biomarkers	Several	Declines with age, exercise increases
Clinical trials	None	Not initiated

SS-31 Clinical Trials

Trial	Phase	Outcome
Barth Syndrome	2/3	Positive (67m 6MWT improvement)
MMPOWER-3 (PMM)	3	Primary endpoint not met
PROGRESS-HF	2	Trends toward improvement
ReCLAIM (AMD)	2	Visual acuity improved
ReCLAIM-2	2b	Ongoing

Research Focus

MOTS-c Research Areas

Area	Evidence Level	Rationale
Metabolic syndrome	Preclinical	AMPK activation
Type 2 diabetes	Biomarker + preclinical	Glucose regulation
Aging/healthspan	Preclinical	Exercise mimetic
Exercise physiology	Biomarker	Increases with exercise

SS-31 Clinical Targets

Area	Trial Status	Rationale
Barth Syndrome	Phase 2/3 positive	Cardiolipin defect
Primary mitochondrial myopathy	Phase 3 mixed	Mito dysfunction
Heart failure	Phase 2 trends	Cardiac mitochondria
Dry AMD	Phase 2b ongoing	Retinal mitochondria

Exercise Mimetic Comparison

Aspect	MOTS-c	SS-31
Exercise Connection	Direct (increases with exercise)	Indirect (improves capacity)
AMPK Activation	Primary mechanism	Not primary
Metabolic Effects	Direct mimetic	Secondary
Muscle Effects	Metabolic improvement	Structural/energetic

MOTS-c as Exercise Mimetic

• Levels increase with exercise in humans
• Activates same AMPK pathways as exercise
• Produces similar metabolic improvements (animal)
• True “exercise in a molecule” candidate

SS-31 and Exercise Capacity

• Improves mitochondrial function for exercise
• Enhanced ATP production
• Reduced fatigue (animal studies)
• Indirect exercise enhancement

Administration

Aspect	MOTS-c	SS-31
Route (research)	Subcutaneous	Subcutaneous, IV
Half-life	Under study	Hours
Stability	Being characterized	Good
Pharmaceutical Grade	No	Yes (clinical trials)

Safety Profiles

MOTS-c

Concern	Status
Human safety data	None
Endogenous nature	May suggest tolerability
mTOR suppression	Long-term effects unknown
Metabolic effects	Blood sugar monitoring

SS-31 (Clinical Trial Data)

Effect	Frequency	Notes
Injection site reactions	Common	Transient
Headache	Occasional	Mild-moderate
Generally well-tolerated	Yes	No major safety signals

Aging/Longevity Research

MOTS-c Aging Data

Model	Finding	Source
Aged mice (22 mo)	Improved physical capacity	Reynolds 2021
K14Q variant	Associated with longevity	Japanese studies
Age decline	Levels decrease with age	Multiple

SS-31 Aging Data

Model	Finding	Source
Aged mice	1-hour treatment reversed dysfunction	Siegel 2013
Aged muscle	Improved fatigue resistance	Multiple
Aged heart	Improved function	Sabbah 2016

Synergy Potential

Factor	Consideration
Complementary mechanisms	Signaling + structural
Different targets	AMPK vs cardiolipin
Combined effect	Metabolic + bioenergetic
Interaction data	None available

Regulatory and Availability

Aspect	MOTS-c	SS-31
FDA Status	Not approved	Investigational drug
Clinical Access	Research only	Via trials/named patient
Research Grade	Available	Available (expensive)
Quality Control	Variable	High (clinical grade)
Cost	Moderate	Very high

Summary

Factor	MOTS-c	SS-31 (Elamipretide)
Type	Endogenous MDP	Synthetic drug
Mechanism	AMPK/metabolic	Cardiolipin binding
Clinical Status	No trials	Phase 2/3
Human Safety Data	None	Established
Evidence Level	Low	Moderate
Exercise Connection	Direct mimetic	Indirect enhancement
Path to Market	None	Active
Availability	Research chemical	Clinical trials/high cost

Key Takeaways

1. Different origins: MOTS-c is endogenous; SS-31 is rationally designed
2. SS-31 is clinical-stage: Active Phase 2/3 trials vs MOTS-c with no trials
3. Different mechanisms: MOTS-c signals via AMPK; SS-31 binds cardiolipin directly
4. MOTS-c is exercise mimetic: True mimetic of exercise metabolic effects
5. SS-31 has safety data: Established profile from trials; MOTS-c has none
6. Both target mitochondria: Complementary approaches to mito health
7. SS-31 may gain approval: Ongoing trials could lead to FDA approval
8. MOTS-c lacks development: Despite compelling data, no clinical path

---

This comparison is for educational purposes only. SS-31 is an investigational drug. MOTS-c is a research compound. Neither is FDA-approved for any indication.